Outcome of patients with carbapenem-resistant Acinetobacter baumannii infections treated with cefiderocol: A multicenter observational study

World Health Organization. 2021. WHO publishes list of bacteria for which new antibiotics are urgently needed. https://www.who.int/news/item/27–02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

European Centre for Disease Prevention and Control; Antimicrobial Resistance Surveillance in Europe 2022–2020 Data. [(accessed on 1 November 2022)]. Available online: https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022–2020-data.

Trama U., Signoriello G., D’Agostino F., Sarnelli B.Rapporto 2019 sull’antibiotico resistenza e sull’uso di antibiotici rilevati nelle strutture pubbliche del sistema sanitario della Campania. Assessorato alla Sanità della Regione Campania, Direzione Generale per la Tutela della Salute ed il Coordinamento del Sistema Sanitario Regionale [(accessed on 1 November 2022)]. Available online: http://www.regione.campania.it/regione/it/tematiche/antibiotico-resistenza-ed-infezioni-correlate-all-assistenza-64in.

Coppola, 2022, Epidemiology, mechanisms of resistance and treatment algorithm for infections due to carbapenem-resistant gram-negative bacteria: an expert panel opinion, Antibiotics, 11, 1263, 10.3390/antibiotics11091263

Paul, 2022, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine), Clin Microbiol Infect, 28, 521, 10.1016/j.cmi.2021.11.025

Longshaw, 2020, In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe, JAC Antimicrob Resist, 10.1093/jacamr/dlaa060

Bassetti, 2021, Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial, Lancet Infect Dis, 21, 226, 10.1016/S1473-3099(20)30796-9

Falcone, 2022, Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant acinetobacter baumannii, Antimicrob Agents Chemother, 66, 10.1128/aac.02142-21

Reilly, 2016, The reliability of the McCabe score as a marker of co-morbidity in healthcare-associated infection point prevalence studies, J Infect Prev, 17, 127, 10.1177/1757177415617245

CDC, 2021. CDC/NHSN Surveillance Definitions for Specific Types of Infections. Available online: https://www.cdc.gov/nhsn/pdfs/pscmanual/17pscnosinfdef_current.pdf.

Singer, 2016, The third international consensus definitions for sepsis and septic shock (Sepsis-3), J Am Med Assoc, 315, 801, 10.1001/jama.2016.0287

Jones, 2009, The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation, Crit Care Med, 37, 1649, 10.1097/CCM.0b013e31819def97

Hilf, 1989, Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients, Am J Med, 87, 540, 10.1016/S0002-9343(89)80611-4

Pugin, 1991, Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid, Am Rev Respir Dis, 143, 1121, 10.1164/ajrccm/143.5_Pt_1.1121

Hsueh, 2021, Clinical efficacy and safety of cefiderocol in the treatment of acute bacterial infections: a systematic review and meta-analysis of randomised controlled trials, J Glob Antimicrob Resist, 24, 376, 10.1016/j.jgar.2021.02.004

Falcone, 2021, Cefiderocol as rescue therapy for acinetobacter baumannii and other carbapenem-resistant gram-negative infections in intensive care unit patients, Clin Infect Dis, 72, 2021, 10.1093/cid/ciaa1410

Pascale, 2021, Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study, JAC Antimicrob Resist, 3, dlab174, 10.1093/jacamr/dlab174

Sirijatuphat, 2014, Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumanniiinfections, Antimicrob Agents Chemother, 58, 5598, 10.1128/AAC.02435-13

Lodise, 2022, All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies, Expert Rev Anti Infect Ther, 20, 707, 10.1080/14787210.2022.2020099

Kaye, 2023, Colistin monotherapy versus combination therapy for carbapenem-resistant organisms, NEJM Evid, 2, 10.1056/EVIDoa2200131

Appaneal, 2022, Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with acinetobacter baumannii infection, Antimicrob Agents Chemother, 66, 10.1128/aac.01975-21

Russo, 2019, ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study, J Infect, 79, 130, 10.1016/j.jinf.2019.05.017

Gill, 2023, In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii, J Antimicrob Chemother, 78, 983, 10.1093/jac/dkad032